about
Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viabilityActivated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylationc-Abl is required for development and optimal cell proliferation in the context of p53 deficiencyFunctional role for the c-Abl tyrosine kinase in meiosis IDasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinasesRapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer.Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA bindingRegulation of sensitivity to TRAIL by the PTEN tumor suppressor.Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistanceNeoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions?Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells.Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest.p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression.Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells.PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway.Role for c-Abl tyrosine kinase in growth arrest response to DNA damage.Signal transduction by wild-type and leukemogenic Abl proteins.Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer.A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels.Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene.Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.Arrays of High-Aspect Ratio Microchannels for High-Throughput Isolation of Circulating Tumor Cells (CTCs).ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate CancerPhase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapyCutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-seriesRegulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinaseRenal cell carcinomaNeoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trialResponse to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancerGenomic Profiling of Cancers of Unknown Primary Site: The Next StepsPhase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer
P50
Q28240677-F9B489FA-E464-4135-ACAB-3A66D3ECF03EQ28301664-86A147CD-FEDF-4A2B-861E-5B2A452C5D4BQ28511871-4314A901-95E5-4042-8E1C-1511E78AD581Q28570715-5DA6BB5E-B3D7-4155-A8BB-9EA9BEC1F0B0Q30433918-10FFEEC5-7305-4262-AE05-73B6C954141AQ33903478-B865F679-A794-4AFE-AB97-145BF611325BQ34441553-5AD5D47C-2676-4D0F-AAE6-71F817D4149DQ34451657-BE216C4E-5AD7-4415-B417-B1F7786688B9Q35624046-4FA1343F-D648-4120-ACFB-9B68B333FAE2Q35756915-6E28531D-6D01-4872-8206-C50639E6C9D0Q36398998-4877EEA4-4DC6-45E8-8676-DCB7F60A5FD9Q36470627-A360EC8D-5A44-4538-9DCA-A1F02C677F78Q37375315-1E7AC42F-8EDE-4CC9-A84F-24C4A8EC6A69Q37540839-1FE7BF4B-703B-4E68-9FB0-1CDCD82F2710Q38220073-AC764FFD-03A3-4019-B519-66BF44B15FBDQ39580436-ED1616C6-E9B4-42A9-95AC-FB8638BB2D09Q40272298-17B23543-D225-4684-A618-682DB57D5B5BQ40358053-579C18C2-709A-4C62-A31D-A08AB74E4C84Q40404616-DC600C87-13AD-4309-8CBA-D85958A93B1CQ40434329-9AAAC59E-8F0F-4785-8422-9E4AAEEA4F89Q40448896-577C7D89-EAEB-4911-B9CE-03D17E356245Q40648400-CA85275F-1043-4A32-A9F0-59590D038436Q40755882-2BDAE096-A0BF-4481-8081-190D3C95BCBBQ41183906-4C692AA1-70EC-4EBC-BC78-21788E462C4FQ41679375-F0AF3DDB-857A-4402-86A3-662ADDA61310Q42370326-95C4921E-D34F-42E5-B583-959C06EEAD35Q43188531-34F811A4-D216-4644-9F30-00FA17078A5CQ45038240-4DA45156-1508-48A2-AED2-B63D5BAB1C76Q46894426-372ADF1C-2CC7-42E3-B19F-33173B02F322Q47562402-1167674B-42FD-40D2-993F-E9DC0EFBE8E6Q53403386-9EEF033B-7E35-4423-BD55-0D85DCBE90CEQ56886543-1E59537A-96A3-4780-90CA-B8D22B11AE6FQ57180547-1BA23846-E37B-498A-ACF2-6C2BB0E4E379Q60917189-17BBAAD3-FF24-40EF-8F5D-CF262AE5553EQ64388536-D03EB91A-FA73-415A-968E-8A1DF57189ABQ73460093-875E92F4-DD9B-4F94-AE22-25020A13AB52Q82293256-BA3DA03A-5C20-4ABB-AB41-CF0094AB0298Q83500868-CC7AB7C9-F2EF-4728-8E78-C0E8B370B810Q85609604-DE0B3FCA-E395-4269-9A0D-FEB41FB43C00Q87385485-4BE680E4-845F-4BD7-A148-0447A4960D6D
P50
description
researcher
@en
name
Whang Y
@nl
Young Whang
@en
type
label
Whang Y
@nl
Young Whang
@en
altLabel
Whang Y
@en
prefLabel
Whang Y
@nl
Young Whang
@en
P106
P31
P496
0000-0002-1621-6661